Monitor for underwriter option exercise within 30 days; assess dilution impact given new shares issued and pre-funded warrants outstanding. Evaluate use of proceeds against pipeline milestones to determine capital efficiency.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 11 $85.84entry
- T+1 · 8mo ago −6.43%α −4.95% · $80.32
- T+5 · 8mo ago −8.13%α −5.94% · $78.86
- T+20 · 7mo ago +6.78%α +6.26% · $91.66
- T+60 · 6mo ago −1.01%α −12.54% · $84.97
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Dianthus Therapeutics priced an upsized public offering of 7,313,582 shares at $81.00 per share and pre-funded warrants for 402,468 additional shares at $80.999, raising approximately $625 million in gross proceeds. The funds will support clinical development, commercial readiness, and general corporate purposes, with a 30-day underwriter option to purchase up to an additional 1,157,407 shares.
Key Financial Metrics
Key Facts
- Priced public offering of 7,313,582 common shares at $81.00 per share
- Pre-funded warrants issued for 402,468 shares at $80.999, exercisable immediately at $0.001 per share
- Total gross proceeds: ~$625 million (before expenses)
- Underwriters granted 30-day option to purchase up to 1,157,407 additional shares
- Proceeds to fund clinical and preclinical programs, commercial readiness, and general corporate use
- Offering expected to close on March 12, 2026, subject to customary conditions
Financial Impact
$625 million in gross proceeds, with potential for ~$93.8 million more if underwriters fully exercise option (1,157,407 shares × $81)
Risk Factors
- Significant near-term dilution from new shares and pre-funded warrants
- Proceeds dependent on biotech R&D success, which carries high clinical failure risk
- No guarantee that capital will lead to commercial or regulatory success
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3253481 |
Track record
23 reports on DNTH
7 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +41.40% at T+60 after the Jun 11, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $89.76 Now $89.55 −0.23% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 3/10 Entry $88.81 to $89.30 Now $89.55 +0.83% ▲ +0.55% −0.77% vs SPY
- Nov 4, 202612d ago 8-K Neutral 4/10 No price data
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $83.01 to $86.03 Now $89.55 +7.88% ▲ +3.64% +3.33% vs SPY
- Oct 30, 202617d ago Institutional Cluster Neutral 3/10 Entry $82.38 to $82.25 Now $89.55 +8.70% ▼ −0.16% +0.32% vs SPY
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $82.38 to $82.25 Now $89.55 +8.70% ▼ −0.16% +0.32% vs SPY
- Oct 12, 20265w ago Institutional Cluster Mixed 3/10 Entry $81.57 to $77.58 Now $89.55 +9.78% ▼ −4.89% −4.88% vs SPY
- Aug 11, 202613w ago Insider Cluster Neutral 4/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
- Aug 11, 202613w ago Insider Cluster Neutral 3/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
- Aug 11, 202613w ago Insider Cluster Neutral 3/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers